--- title: "Did You Lose Money on Biohaven Ltd. (BHVN)? Levi & Korsinsky Urges Investors to Act Before September 12, 2025" description: "Levi & Korsinsky LLP is urging investors who lost money on Biohaven Ltd. (BHVN) to act before September 12, 2025, regarding a class action lawsuit related to alleged securities fraud. The lawsuit clai" type: "news" locale: "en" url: "https://longbridge.com/en/news/252378205.md" published_at: "2025-08-10T11:22:00.000Z" --- # Did You Lose Money on Biohaven Ltd. (BHVN)? Levi & Korsinsky Urges Investors to Act Before September 12, 2025 > Levi & Korsinsky LLP is urging investors who lost money on Biohaven Ltd. (BHVN) to act before September 12, 2025, regarding a class action lawsuit related to alleged securities fraud. The lawsuit claims that the company made false statements about its product candidates, which negatively impacted its business and financial condition. Investors who suffered losses between March 24, 2023, and May 14, 2025, are encouraged to seek recovery without any cost or obligation. Levi & Korsinsky has a strong track record in securities litigation. **NEW YORK, NY / ACCESS Newswire / August 10, 2025 /** If you suffered a loss on your **Biohaven Ltd.** investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=160641&wire=1&utm\_campaign=28 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates. **THE LAWSUIT:** A class action securities lawsuit was filed against Biohaven Ltd. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025. **CASE DETAILS:** The filed complaint alleges that defendants made false statements and/or concealed that: (i) The company's product candidate, troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven's business and financial condition; and (iv) as a result, defendants' public statements were materially false and misleading at all relevant times. **WHAT'S NEXT?** If you suffered a loss in Biohaven Ltd. stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=160641&wire=1&utm\_campaign=28 to learn about your rights to seek a recovery. **There is no cost or obligation to participate.** **WHY LEVI & KORSINSKY:** Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes. **CONTACT:** Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 jlevi@levikorsinsky.com Tel: (212) 363-7500 Fax: (212) 363-7171 https://zlk.com/ **SOURCE:** Levi & Korsinsky, LLP View the original press release on ACCESS Newswire ### Related Stocks - [BHVN.US - Biohaven Pharmaceutical](https://longbridge.com/en/quote/BHVN.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Biohaven highlights degrader platforms in new investor presentation | Biohaven Ltd. (BHVN) announced an investor presentation on January 12, 2026, detailing advancements in its drug developm | [Link](https://longbridge.com/en/news/272300228.md) | | Biohaven Ltd Announces Investor Presentation on January 12, 2026 | Biohaven Ltd will hold an investor presentation on January 12, 2026, showcasing its novel degrader platform for autoimmu | [Link](https://longbridge.com/en/news/272297879.md) | | Biohaven reports Phase II BHV-7000 trial results for MDD | Biohaven announced Phase II trial results for BHV-7000 in MDD, showing no primary endpoint achievement but trends favori | [Link](https://longbridge.com/en/news/270844475.md) | | Biohaven Misses The Mark In Depression Trial, Stock Falls | Biohaven's Phase 2 study with BHV-7000 for major depressive disorder did not meet its primary endpoint, leading to a 15. | [Link](https://longbridge.com/en/news/270854796.md) | | Biohaven Reports Promising Phase 1 Results for BHV-1510 in Combination with Cemiplimab in Advanced Solid Tumors | Biohaven Ltd. announced promising Phase 1 trial results for BHV-1510 combined with cemiplimab in advanced solid tumors. | [Link](https://longbridge.com/en/news/269376483.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.